Drug Shortage Report for TEVA-IRBESARTAN
| Report ID | 94369 |
| Drug Identification Number | 02316404 |
| Brand name | TEVA-IRBESARTAN |
| Common or Proper name | IRBESARTAN |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | IRBESARTAN |
| Strength(s) | 150MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 100 |
| ATC code | C09CA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, PLAIN |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2019-09-18 |
| Estimated end date | 2021-09-30 |
| Actual end date | 2021-09-09 |
| Shortage status | Resolved |
| Updated date | 2021-09-10 |
| Company comments | Will continue to allocate until regular supply can be restored (TBA) Allocating 100% of Teva market share from July to August. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2019-09-19 | English | Compare |